China lifts some pricing restrictions

Share this article:

Poor quality and drug shortages appear to be behind China's recent decision to end price caps on some low-cost drugs. The Wall Street Journal reports that the change will affect 280 medications made by Western drug companies and will have an impact on items including antibiotics, painkillers and vitamins.

The WSJ notes that China has put significant pressure on prices in an effort to keep health costs down, which encouraged manufacturers to either stop making drugs because of the lack of profit (which is what happened with thyroid medication Tapazole), or swap in cheaper ingredients, such as industrial gelatin—a carcinogen—instead of pharma-grade gelatin to save money.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.